Nezglyal receives positive CHMP opinion supporting treatment access for boys with cALD

RegulatorypositiveNezglyalPositive

AI Analysis

Summary

Nezglyal received a positive CHMP opinion, bringing it closer to European regulatory approval for treating cerebral adrenoleukodystrophy in boys. The positive recommendation from European regulators supports expanded treatment access for this patient population.

Outcome Details

Positive CHMP (Committee for Medicinal Products for Human Use) opinion

Importance:7/10

Sentiment:

0.75

European approvalCHMP opinionRare diseasePediatric indication

Related Companies

$OPTN

Read the original article

Published by PharmaTimes on July 28, 2026 10:03 AM

Read Original